Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 33 | 2023 | 111 | 7.410 |
Why?
|
| Sarcoma | 15 | 2023 | 138 | 2.610 |
Why?
|
| Bone Substitutes | 9 | 2017 | 23 | 2.160 |
Why?
|
| Soft Tissue Neoplasms | 7 | 2022 | 55 | 1.810 |
Why?
|
| Bone Transplantation | 8 | 2017 | 197 | 1.690 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 15 | 1.640 |
Why?
|
| Sarcoma, Ewing | 3 | 2020 | 6 | 1.470 |
Why?
|
| Calcium Sulfate | 6 | 2012 | 18 | 1.110 |
Why?
|
| Musculoskeletal Diseases | 2 | 2015 | 40 | 0.960 |
Why?
|
| Limb Salvage | 5 | 2023 | 11 | 0.930 |
Why?
|
| Humans | 61 | 2023 | 25178 | 0.910 |
Why?
|
| Retrospective Studies | 27 | 2023 | 3105 | 0.860 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 182 | 0.840 |
Why?
|
| Hip Joint | 2 | 2016 | 376 | 0.780 |
Why?
|
| Adult | 24 | 2022 | 7087 | 0.770 |
Why?
|
| Young Adult | 13 | 2021 | 1749 | 0.760 |
Why?
|
| Adolescent | 16 | 2021 | 1998 | 0.750 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 21 | 0.730 |
Why?
|
| Osteosarcoma | 8 | 2021 | 34 | 0.710 |
Why?
|
| Child | 13 | 2021 | 1232 | 0.710 |
Why?
|
| Calcium Phosphates | 2 | 2012 | 22 | 0.700 |
Why?
|
| Child, Preschool | 9 | 2021 | 588 | 0.660 |
Why?
|
| Fractures, Bone | 2 | 2012 | 73 | 0.660 |
Why?
|
| Bone Cysts | 2 | 2016 | 2 | 0.650 |
Why?
|
| Synovitis, Pigmented Villonodular | 2 | 2016 | 2 | 0.650 |
Why?
|
| Tibia | 2 | 2010 | 228 | 0.620 |
Why?
|
| Treatment Outcome | 16 | 2023 | 3146 | 0.600 |
Why?
|
| Male | 26 | 2021 | 13545 | 0.590 |
Why?
|
| Middle Aged | 21 | 2021 | 8135 | 0.570 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2022 | 584 | 0.560 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 3 | 0.550 |
Why?
|
| Bone Diseases | 2 | 2017 | 22 | 0.540 |
Why?
|
| Female | 23 | 2021 | 13844 | 0.540 |
Why?
|
| Internal Fixators | 1 | 2016 | 37 | 0.540 |
Why?
|
| Foot | 1 | 2016 | 31 | 0.530 |
Why?
|
| Acetabulum | 3 | 2016 | 194 | 0.530 |
Why?
|
| Arthrodesis | 2 | 2014 | 41 | 0.530 |
Why?
|
| Radiotherapy | 1 | 2016 | 31 | 0.520 |
Why?
|
| Foreign Bodies | 1 | 2016 | 28 | 0.520 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 33 | 0.520 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 59 | 0.510 |
Why?
|
| Radius | 2 | 2014 | 31 | 0.490 |
Why?
|
| Knee Prosthesis | 2 | 2008 | 214 | 0.460 |
Why?
|
| Tobramycin | 2 | 2005 | 9 | 0.460 |
Why?
|
| Survival Rate | 5 | 2021 | 310 | 0.450 |
Why?
|
| Biopsy | 6 | 2023 | 191 | 0.430 |
Why?
|
| Arthralgia | 2 | 2011 | 111 | 0.420 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 326 | 0.420 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 30 | 0.410 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 268 | 0.400 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 33 | 0.400 |
Why?
|
| Prognosis | 8 | 2023 | 726 | 0.390 |
Why?
|
| Talus | 1 | 2011 | 9 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 49 | 0.380 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 3 | 0.380 |
Why?
|
| Allografts | 4 | 2021 | 187 | 0.380 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 1621 | 0.370 |
Why?
|
| Edema | 1 | 2011 | 24 | 0.370 |
Why?
|
| Patellar Ligament | 1 | 2010 | 38 | 0.360 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 484 | 0.350 |
Why?
|
| Humerus | 3 | 2005 | 99 | 0.340 |
Why?
|
| Prosthesis Failure | 4 | 2022 | 482 | 0.340 |
Why?
|
| Osteomyelitis | 3 | 2005 | 19 | 0.320 |
Why?
|
| Debridement | 3 | 2016 | 88 | 0.320 |
Why?
|
| Femur | 4 | 2022 | 352 | 0.320 |
Why?
|
| Reoperation | 6 | 2022 | 807 | 0.310 |
Why?
|
| Bone Plates | 1 | 2008 | 49 | 0.300 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 57 | 0.290 |
Why?
|
| Aged | 12 | 2021 | 8397 | 0.280 |
Why?
|
| Cisplatin | 3 | 2017 | 46 | 0.280 |
Why?
|
| Osteogenesis | 1 | 2007 | 96 | 0.270 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 754 | 0.260 |
Why?
|
| Orthopedic Procedures | 3 | 2004 | 272 | 0.250 |
Why?
|
| Curettage | 3 | 2022 | 8 | 0.250 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 152 | 0.240 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 4503 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 61 | 0.240 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 300 | 0.240 |
Why?
|
| Transplantation, Homologous | 2 | 2004 | 249 | 0.230 |
Why?
|
| Infant | 3 | 2021 | 483 | 0.230 |
Why?
|
| Margins of Excision | 2 | 2022 | 27 | 0.230 |
Why?
|
| Joint Instability | 1 | 2008 | 344 | 0.230 |
Why?
|
| Pelvic Bones | 1 | 2004 | 16 | 0.230 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 78 | 0.230 |
Why?
|
| Knee Joint | 2 | 2008 | 681 | 0.220 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 34 | 0.220 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 41 | 0.210 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 62 | 0.210 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 294 | 0.210 |
Why?
|
| Injections | 2 | 2016 | 41 | 0.210 |
Why?
|
| Neutrophils | 1 | 2023 | 90 | 0.210 |
Why?
|
| Prostheses and Implants | 2 | 2015 | 150 | 0.210 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 685 | 0.200 |
Why?
|
| Absorbable Implants | 1 | 2002 | 21 | 0.200 |
Why?
|
| Infant, Newborn | 2 | 2021 | 522 | 0.200 |
Why?
|
| Apoptosis | 5 | 2022 | 187 | 0.200 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 11 | 0.200 |
Why?
|
| Vancomycin | 1 | 2002 | 50 | 0.200 |
Why?
|
| Bone Cements | 3 | 2022 | 88 | 0.200 |
Why?
|
| Radiography | 5 | 2015 | 572 | 0.200 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 9 | 0.190 |
Why?
|
| Myxosarcoma | 1 | 2020 | 3 | 0.180 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 9 | 0.180 |
Why?
|
| Orthopedics | 1 | 2002 | 100 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hip Prosthesis | 2 | 2022 | 516 | 0.170 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 179 | 0.170 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 17 | 0.170 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 232 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 7 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 13 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 175 | 0.160 |
Why?
|
| Dogs | 4 | 2007 | 176 | 0.160 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 58 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2019 | 35 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 66 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 80 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 94 | 0.150 |
Why?
|
| Osteoarthritis | 1 | 2022 | 303 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 79 | 0.150 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 4 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 45 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 209 | 0.140 |
Why?
|
| Imidazoles | 1 | 2017 | 59 | 0.140 |
Why?
|
| Piperazines | 1 | 2017 | 75 | 0.140 |
Why?
|
| Ceramics | 1 | 2016 | 22 | 0.140 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 10 | 0.130 |
Why?
|
| Synovectomy | 1 | 2016 | 4 | 0.130 |
Why?
|
| Chondroma | 3 | 2012 | 5 | 0.130 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 87 | 0.130 |
Why?
|
| Child Development | 1 | 2016 | 67 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 1756 | 0.130 |
Why?
|
| Time Factors | 3 | 2022 | 1327 | 0.120 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 3 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 108 | 0.120 |
Why?
|
| Prosthesis Design | 3 | 2022 | 462 | 0.120 |
Why?
|
| Supination | 1 | 2014 | 19 | 0.120 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 89 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 29 | 0.120 |
Why?
|
| Ossification, Heterotopic | 1 | 2015 | 31 | 0.120 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 374 | 0.120 |
Why?
|
| Arthroplasty | 1 | 2016 | 130 | 0.120 |
Why?
|
| Lung | 1 | 2015 | 153 | 0.120 |
Why?
|
| Hand Strength | 1 | 2014 | 56 | 0.120 |
Why?
|
| Risk Factors | 2 | 2022 | 2166 | 0.120 |
Why?
|
| Wrist Joint | 1 | 2014 | 61 | 0.120 |
Why?
|
| Drug Implants | 2 | 2005 | 8 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2014 | 13 | 0.110 |
Why?
|
| Telomerase | 2 | 2004 | 9 | 0.110 |
Why?
|
| Spinal Fusion | 1 | 2020 | 452 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 1113 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2013 | 1 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 92 | 0.110 |
Why?
|
| Recovery of Function | 2 | 2012 | 264 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2013 | 15 | 0.110 |
Why?
|
| Bone Matrix | 2 | 2003 | 24 | 0.100 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2012 | 3 | 0.100 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 26 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 47 | 0.100 |
Why?
|
| Bone Regeneration | 2 | 2003 | 68 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 332 | 0.100 |
Why?
|
| Animals | 5 | 2007 | 3377 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 27 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 35 | 0.100 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 645 | 0.100 |
Why?
|
| Ankle | 1 | 2011 | 16 | 0.090 |
Why?
|
| Thoracoscopy | 1 | 2010 | 20 | 0.090 |
Why?
|
| Ilium | 1 | 2010 | 27 | 0.090 |
Why?
|
| Age Factors | 2 | 2019 | 720 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 315 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 438 | 0.080 |
Why?
|
| Chicago | 1 | 2012 | 782 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2008 | 233 | 0.070 |
Why?
|
| Compressive Strength | 1 | 2007 | 21 | 0.070 |
Why?
|
| Elasticity | 1 | 2007 | 31 | 0.070 |
Why?
|
| Illinois | 1 | 2008 | 222 | 0.070 |
Why?
|
| Cell Division | 3 | 2022 | 71 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1589 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2006 | 31 | 0.070 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 6 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 86 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 19 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2006 | 46 | 0.070 |
Why?
|
| Proteins | 1 | 2006 | 54 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2006 | 83 | 0.070 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 13 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2016 | 135 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 307 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 278 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 74 | 0.060 |
Why?
|
| Blastomycosis | 1 | 2004 | 17 | 0.060 |
Why?
|
| Arthroscopy | 1 | 2011 | 816 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2023 | 37 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 94 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2023 | 49 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 306 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 52 | 0.050 |
Why?
|
| Bone Demineralization Technique | 1 | 2003 | 3 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 17 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 16 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 51 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 117 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 10 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 10 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2003 | 74 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 27 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2016 | 380 | 0.050 |
Why?
|
| Replantation | 1 | 2022 | 8 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 27 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 2 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 85 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 8 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 16 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 30 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 46 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 41 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 77 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2004 | 592 | 0.050 |
Why?
|
| Cartilage | 1 | 2002 | 93 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 45 | 0.050 |
Why?
|
| SEER Program | 1 | 2021 | 39 | 0.050 |
Why?
|
| DNA Damage | 2 | 2014 | 26 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2002 | 407 | 0.040 |
Why?
|
| Tendons | 1 | 2002 | 185 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 588 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 97 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 117 | 0.040 |
Why?
|
| Mesna | 1 | 2019 | 2 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2019 | 12 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 6 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 46 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 51 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 72 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 10 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 38 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 6 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 154 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 5 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 29 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 41 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 63 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 7 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1992 | 18 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 63 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1992 | 124 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 42 | 0.020 |
Why?
|
| Acridine Orange | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 5 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2006 | 13 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 90 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 57 | 0.020 |
Why?
|
| Cell Survival | 1 | 2006 | 102 | 0.020 |
Why?
|
| Manubrium | 1 | 2004 | 2 | 0.010 |
Why?
|
| Sternoclavicular Joint | 1 | 2004 | 5 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2004 | 136 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 94 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 164 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 23 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2002 | 4 | 0.010 |
Why?
|
| Telomere | 1 | 2002 | 5 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 46 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 250 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 86 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 240 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 512 | 0.010 |
Why?
|
| Sepharose | 1 | 1992 | 4 | 0.010 |
Why?
|
| Alginates | 1 | 1992 | 4 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 4 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 5 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 12 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 18 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1992 | 51 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 23 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 33 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 145 | 0.010 |
Why?
|
| Aggrecans | 1 | 1992 | 61 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 467 | 0.010 |
Why?
|